Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Alpha Tau (DRTS) AI Stock Analysis

0 Followers
IL:DRTS

Alpha Tau

(TASE:DRTS)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Localized Alpha RadiationAlpha DaRT’s localized delivery approach addresses a central challenge in cancer treatment: destroying tumor tissue while limiting harm to healthy areas. If clinical evidence supports this intended profile, the technology could provide a differentiated platform applicable across multiple solid-tumor indications.
Negative Factors
No Revenue and Widening LossesThe absence of revenue and widening losses show that Alpha Tau remains dependent on development spending rather than an established commercial business. Without a revenue ramp, operating expenses may continue to pressure earnings and delay the transition to self-funded growth.

Alpha Tau (DRTS) vs. iShares MSCI Israel ETF (EIS)

-20%-10%0%10%20%30%40%IL:DRTS+3.52%EIS+10.58%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
ILS 1.30B
Dividend Yield
―
Average Volume (3M)
23.86K
Price to Earnings (P/E)
-14.1
Beta (1Y)
0.21
Revenue Growth
―
EPS Growth
-82.25%
Country
Israel
Employees
121
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Alpha Tau Business Overview & Revenue Model

Company Description

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technolog...

Alpha Tau Risk Analysis

Alpha Tau disclosed 81 risk factors in its most recent earnings report. Alpha Tau reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Alpha Tau Peers Comparison

Overall Rating

Financial Indicators

IL:DRTS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-10%-5%0%5%IL:DRTSSep '26Oct '26Nov '26
IL:DRTS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IL:DRTSAlpha Tau4556.00155.003.52%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.